Wilson Y. Szeto
University of Pennsylvania
378 Papers
2.3K Citations
Wilson Y. Szeto is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Valve replacement. The author has an hindex of 61, co-authored 329 publications. Previous affiliations of Wilson Y. Szeto include Washington University in St. Louis & University of Virginia.
Chat about Author
Papers
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.
Martin B. Leon,Craig R. Smith,Michael J. Mack,Michael J. Mack,Rajendra Makkar,Lars G. Svensson,Susheel Kodali,Vinod H. Thourani,Murat Tuzcu,D. Craig Miller,Howard C. Herrmann,Darshan Doshi,David J. Cohen,Augusto D. Pichard,Samir R. Kapadia,Todd M. Dewey,Vasilis Babaliaros,Wilson Y. Szeto,Mathew R. Williams,Dean J. Kereiakes,Alan Zajarias,Kevin L. Greason,Brian Whisenant,Robert W. Hodson,Jeffrey W. Moses,Alfredo Trento,David L. Brown,William F. Fearon,Philippe Pibarot,Rebecca T. Hahn,Wael A. Jaber,William N. Anderson,Maria Alu,John G. Webb +33 more
TL;DR: In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke; surgery resulted in fewer major vascular complications and less paravalvular aorta regurgitation.
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
Michael J. Mack,Martin B. Leon,Vinod H. Thourani,Raj Makkar,Susheel Kodali,Mark J. Russo,Samir R. Kapadia,S. Chris Malaisrie,David J. Cohen,Philippe Pibarot,Jonathon Leipsic,Rebecca T. Hahn,Philipp Blanke,Mathew R. Williams,James M. McCabe,David L. Brown,Vasilis Babaliaros,Scott M. Goldman,Wilson Y. Szeto,Philippe Généreux,Ashish Pershad,Stuart J. Pocock,Maria Alu,John G. Webb,Craig R. Smith +24 more
TL;DR: Among patients with severe aortic stenosis who were at low surgical risk, the rate of the composite of death, stroke, or rehospitalization at 1 year was significantly lower with TAVR than with surgery.
4.1K
Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement
Susheel Kodali,Mathew R. Williams,Craig R. Smith,Lars G. Svensson,John G. Webb,Raj Makkar,Gregory P. Fontana,Todd M. Dewey,Vinod H. Thourani,Augusto D. Pichard,Michael P. Fischbein,Wilson Y. Szeto,Scott Lim,Kevin L. Greason,Paul S. Teirstein,S. Chris Malaisrie,Pamela S. Douglas,Rebecca T. Hahn,Brian Whisenant,Alan Zajarias,Duolao Wang,Jodi J. Akin,William N. Anderson,Martin B. Leon,Trial Investigators +24 more
TL;DR: A 2-year follow-up of patients in the PARTNER trial supports TAVR as an alternative to surgery in high-risk patients, but paravalvular regurgitation was more frequent after T AVR and was associated with increased late mortality.
Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts.
Lars G. Svensson,Nicholas T. Kouchoukos,D. Craig Miller,Joseph E. Bavaria,Joseph S. Coselli,Michael A. Curi,Holger Eggebrecht,John A. Elefteriades,Raimund Erbel,Thomas G. Gleason,Bruce W. Lytle,R. Scott Mitchell,Christoph A. Nienaber,Eric E. Roselli,Hazim J. Safi,Richard J. Shemin,Gregorio A. Sicard,Thoralf M. Sundt,Wilson Y. Szeto,Grayson H. Wheatley +19 more
TL;DR: The natural history of aortic disease, indications for repair, outcomes after conventional open surgery, currently available devices, and insights from outcomes of randomized studies using stent-grafts for abdominal aorti aneurysm surgery are reviewed; a suggestion for treatment is offered.
906
5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial
Samir R. Kapadia,Martin B. Leon,Raj Makkar,E. Murat Tuzcu,Lars G. Svensson,Susheel Kodali,John G. Webb,Michael J. Mack,Pamela S. Douglas,Vinod H. Thourani,Vasilis Babaliaros,Howard C. Herrmann,Wilson Y. Szeto,Augusto D. Pichard,Mathew R. Williams,Gregory P. Fontana,D. Craig Miller,William N. Anderson,Craig R. Smith,Jodi J. Akin,Michael J. Davidson +20 more
TL;DR: TAVR should be strongly considered for patients who are not surgical candidates for aortic valve replacement to improve their survival and functional status, and Appropriate selection of patients will help to maximise the benefit of TAVR and reduce mortality from severe comorbidities.
836